MedPath

Polymyxin B

Generic Name
Polymyxin B
Brand Names
Casporyn HC, Cortisporin, Dioptrol, Diosporin, Diphen, Maxitrol, Neo-polycin, Neo-polycin HC, Neosporin Ointment, Neosporin Plus Maximum Strength, Neosporin Plus Maximum Strength Cream, Neosporin Solution, Polycin-B, Polysporin, Polytrim, Procomycin, Statrol, Triple Antibiotic
Drug Type
Small Molecule
Chemical Formula
C56H98N16O13
CAS Number
1404-26-8
Unique Ingredient Identifier
J2VZ07J96K
Background

Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosa. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line.

Indication

Polymyxin B is indicated for the treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosa.

Associated Conditions
Acute Otitis Media (AOM), Bacteremia caused by Enterobacter aerogenes, Bacterial Conjunctivitis, Bacterial Infections, Chronic Otitis Media, Escherichia urinary tract infection, Klebsiella bacteraemia, Meningitis caused by Haemophilus influenzae, Meningitis, Bacterial, Ocular Inflammation, Otitis Externa, Otorrhoea, Superficial ocular infections of the conjunctiva caused by susceptible bacteria, Superficial ocular infections of the cornea caused by susceptible bacteria, Urinary Tract Infection, Ocular bacterial infections

FDA Grants QIDP Status to Venus Remedies' Novel Antibiotic VRP-034 for Bloodstream Infections

• Venus Remedies' investigational antibiotic VRP-034 has received Qualified Infectious Disease Product designation from the FDA for treating bloodstream infections, providing benefits including priority review and extended market exclusivity. • The novel polymyxin B formulation utilizes proprietary Renal Guard technology to reduce nephrotoxicity by up to 70% compared to conventional treatments, addressing a major limitation of last-resort antibiotics. • Developed by Venus Medicine Research Centre, VRP-034 maintains therapeutic efficacy against multidrug-resistant Gram-negative bacteria while significantly reducing kidney damage risk that affects up to 60% of patients on standard polymyxin B therapy.
© Copyright 2025. All Rights Reserved by MedPath